Posted by Michael Wonder on 29 Jan 2017
Jardiance (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular death reduction data in label
26 January 2017 - This is the first time the European Commission approved the use of a diabetes treatment for its effect on both blood sugar control and cardiovascular events.
The European Commission has approved an update to the Jardiance (empagliflozin) label to include a change to the indication statement. Jardiance is now indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
The approved product information now includes data on the reduction of risk of cardiovascular death in patients with T2D and established cardiovascular disease disease in addition to data on the improvement of blood sugar control.
Jardiance is the only oral diabetes treatment shown to reduce the risk of CV death in a dedicated cardiovascular outcome trial to date. Jardiance is marketed by Boehringer Ingelheim and Eli Lilly and Company.
